Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H2 2017’, provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Cardiovascular, Infectious Disease, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Respiratory, Genetic Disorders and Other Diseases under development targeting Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects

The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

F. Hoffmann-La Roche Ltd

InflaRx GmbH

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview 9

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 16

Products under Development by Universities/Institutes 21

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development 28

Akari Therapeutics Plc 28

Alexion Pharmaceuticals Inc 28

Alnylam Pharmaceuticals Inc 29

Amgen Inc 29

F. Hoffmann-La Roche Ltd 30

InflaRx GmbH 30

ISU ABXIS Co Ltd 31

Novartis AG 31

NovelMed Therapeutics Inc 32

Noxxon Pharma AG 32

Ophthotech Corp 33

Ra Pharmaceuticals Inc 33

Regeneron Pharmaceuticals Inc 34

Swedish Orphan Biovitrum AB 35

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles 36

AcPepA - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

avacincaptad pegol sodium - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Bikaciomab - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

cemdisiran - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Coversin - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Coversin LA - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

eculizumab - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

eculizumab biosimilar - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

eculizumab biosimilar - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

IFX-1 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

IFX-2 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Mubodina - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

NM-9405 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

NOXD-19 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

NOXD-20 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

NOXD-21 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Protein to Inhibit Complement C5 for Immunology - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

RA-101295 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

RA-101348 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

RA-101495 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

ravulizumab - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

REGN-3918 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

RG-6107 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

SOBI-005 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Synthetic Coversin - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

tesidolumab - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products 92

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products 94

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones 95

Featured News & Press Releases 95

Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 95

Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 95

Sep 19, 2017: Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases 96

Sep 13, 2017: Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis 96

Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa 98

Aug 21, 2017: European Commission Grants New Indication for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) 99

Aug 15, 2017: Alexion Receives Three New U.S. Patents for Soliris (eculizumab), Extending Patent Protection Into 2027 99

Jul 31, 2017: Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 100

Jul 26, 2017: Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases, Provides Update on Zimura 100

Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis 102

Jun 27, 2017: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH 102

Jun 24, 2017: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association 103

Jun 23, 2017: Alexion Receives Positive CHMP Opinion for Soliris for the Treatment of Patients with Refractory Generalized Myasthenia Gravis in the European Union 104

Jun 21, 2017: Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH 105

May 18, 2017: Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association 105

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Pipeline by Akari Therapeutics Plc, H2 2017 28

Pipeline by Alexion Pharmaceuticals Inc, H2 2017 29

Pipeline by Alnylam Pharmaceuticals Inc, H2 2017 29

Pipeline by Amgen Inc, H2 2017 30

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 30

Pipeline by InflaRx GmbH, H2 2017 31

Pipeline by ISU ABXIS Co Ltd, H2 2017 31

Pipeline by Novartis AG, H2 2017 32

Pipeline by NovelMed Therapeutics Inc, H2 2017 32

Pipeline by Noxxon Pharma AG, H2 2017 33

Pipeline by Ophthotech Corp, H2 2017 33

Pipeline by Ra Pharmaceuticals Inc, H2 2017 34

Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 34

Pipeline by Swedish Orphan Biovitrum AB, H2 2017 35

Dormant Products, H2 2017 92

Dormant Products, H2 2017 (Contd..1), H2 2017 93

Discontinued Products, H2 2017 94

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports